[Special Stock] Preparing to Develop 'Clinical Trial Outcome Prediction AI'... DreamCIS Hits Upper Limit
On the 11th, clinical trial contract research organization DreamCIS recorded a limit-up in the early trading session.
On this day, DreamCIS's stock price rose to the maximum price limit (29.77%) compared to the previous trading day, trading at 22,450 KRW. The sharp rise in the stock price was due to the news that DreamCIS is developing an analytical solution to predict clinical trial results in collaboration with a leading domestic medical artificial intelligence (AI) diagnostic solution company.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- President Lee Orders Thorough Investigation and Safety Inspection of Rebar Omission in GTX-A Samsung Station Section
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Choi Jae-ho, a researcher at Hana Securities, said, "This service uses clinical big data accumulated over 20 years and AI to determine the success or failure of clinical trials at the preclinical stage before clinical phases," adding, "It is an important project that will change the paradigm of existing clinical trials and can become an overwhelmingly leading company after development."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing 90 Degrees These Days Actually Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
